Background-Little is known of the prognostic significance of mitral regurgitation (MR) on
Introduction
Transcatheter aortic valve replacement (TAVR) is an effective option in patients with severe aortic stenosis deemed at high or prohibitive risk for conventional surgical aortic valve replacement 1, 2 . A large amount of literature contributed to the understanding of possible factors associated with or predictive of an adverse prognosis [3] [4] [5] . Nevertheless, when considering the baseline co-morbidities, it is unclear whether the coexistence of mitral regurgitation (MR) could worsen the outcome after TAVR. It is also uncertain whether TAVR could exert a beneficial effect on MR severity by reducing afterload.
Available data are limited to small studies [6] [7] [8] . Of note, it has been suggested that the CoreValve Revalving system (CRS), with respect to the Edwards Sapien valve (ESV), may impair the mitral valve function leading to a larger regurgitation as a consequence of an interference with the anterior leaflet 9 .
We thus sought to evaluate, in a multicenter registry of patients undergoing CRS-TAVR, the prognostic significance of different grades of MR on post TAVR outcome, the impact of TAVR on MR severity, and the variables associated with post-TAVR improvement in MR severity.
Methods

Study Design and Patient Population
From June 2007 to April 2011, a total of 1007 consecutive patients affected by severe aortic stenosis have been treated with the third-generation 18-Fr CRS device.
Since commencement of the TAVR experience in Italy, patients treated in the first activated centers were systematically included in a nation-wide registry. This registry has been CoreValve Revalving system (CRS), with respect to the Edwards Sapien valve (E (E ESV SV V), ), , m m may ay ay mpair the mitral valve function leading to a larger regurgitation as a consequence of an n nte te erf rf rfer er eren ence ce ce w w with h h th th the e anterior leaflet 9 .
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All patients were evaluated for TAVR by the local "Heart team" that included: a clinical cardiologist, an interventional cardiologist, a cardiac surgeon and a cardiac anesthesiologist. The evaluation of the "Heart Team" led to the indication for TAVR after careful assessment of all the clinical/anatomical conditions determining a higher risk of mortality/morbidity after surgery. All patients scheduled for TAVR and that gave written consent for the procedure and registry were enrolled. There were no exclusion criteria for inclusion in this registry. However, for the present study, patients with a failed aortic bioprosthesis have been excluded from the analysis and evaluated in a different publication 10 .
Follow-up was scheduled in all patients at 1, 6, 12 months and then yearly.
Patients were followed up by means of outpatient clinics and regular contact with General
Practitioners.
Device and Procedure
The CoreValve prosthesis consists of a trileaflet biological valve sewed in a self-expanding nitinol frame. General anesthesia, local anesthesia or mild sedation were decided by the heart team during the pre-operative meeting. Arterial access (femoral, left or right subclavian), percutaneous puncture or surgical exposure were also determined on the basis of the panel of pre-op imaging tests which included in most of the cases both angiography and CT-scan. After the procedure, most patients were managed in an Intensive Care Unit or Coronary Care Unit for at least a day and a temporary PM was left in place for at least 48 hours. All patients received acetylsalicylic acid (at least 100 mg before the procedure and lifelong) as well as clopidogrel (300mg bolus plus 75 mg daily for 3 to 6 months unless prolonged administration was required for previous coronary intervention with drug-eluting stents). During the intervention, Follow-up was scheduled in all patients at 1, 6, 12 months and then yearly ly y.
Patients were followed up by means of outpatient clinics and regular contact with Genera t Pr rac ac acti ti titi ti tion on ner er ers s.
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In the case of significant concomitant coronary disease, percutaneous intervention was performed before or at the time of TAVR in order to obtain a complete revascularization and minimize the impact of "ischemic" MR on the results.
Data Collection and Definitions
Transthoracic echocardiography was performed before TAVR, within 3 days after TAVR, at 1, 6
and 12 months by a senior cardiologist.
MR severity was graded as none/mild ("0/1"), moderate ("2"), or severe ("3"), while mitral annular calcification as "no" ("0"), "localized to the annulus" ("1") and "extensive", (i.e.
annulus + leaflets, "2"), according to the guidelines of the European Society of Echocardiography [10] . MR etiology has been classified as organic (primary) or functional (secondary). Organic MR is due to intrinsic valvular disease whereas functional MR is caused by regional or global LV remodeling without structural abnormalities of the valve apparatus 11 .
Frailty has been defined according to Winograd and colleagues 12 .
Severe pulmonary hypertension (SPH) was defined as a systolic pulmonary artery pressure >55mmHg. One-year clinical follow up, or a medical record reporting a fatality, was available in 980 patients (97.3%) while echocardiographic follow up was available in 815 patients (97.4% of those who reached 1-year follow-up). Endpoints were defined according to VARC definitions 13 . In particular, cardiac mortality was defined as "Any death due to proximate cardiac cause (e.g., myocardial infarction, cardiac tamponade, worsening heart failure)".
Statistical analysis
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A linear mixed effects model was used to compare the changes in LVEF and EDV at different time points between groups.
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Results
Baseline and procedural features of the study population according to baseline MR severity are shown in Table 1 SPH was more frequent in patients with severe (39%) and moderate MR (25%) compared to patients with mild/none MR (11%). Atrial fibrillation (AF) showed a similar pattern (30%, 23% and 13%, respectively). Severe MR was associated with a larger mean end diastolic volume (124ml vs. 116ml and 105ml). Of note, both LogEuroscore and STS score were significantly higher in patients with severe MR. Likewise the rate of NYHA class 3-4 at presentation. No significant differences were observed across groups as regards to procedural data.
Analysis of mortality
Overall Mortality. o patients with mild/none MR (11%). Atrial fibrillation (AF) showed a similar pa pa att tter e e n n n (3 (3 (30% 0% 0%, , 23% and 13%, respectively). Severe MR was associated with a larger mean end diastolic volume 1 124 24 4ml ml ml v vs. s s. 1 1 11 1 16ml ml ml a a and n 105ml). Of note, both Log g gE E Eu u uroscore and S STS T T s sco co cor re re were significantly h hi high h her e in patien ent ts ts w w wit ith h h se se eve ve ere re re M M MR R. R. L L Lik ik ke ew wise e e t th he r rat te e o of f NY NY NYH HA HA c c cla a ass s 3-3-3 4 4 at at p p pr re rese sen n ntat at atio io i n. n. N N No o o i ign gn gnif if fic ic ican ant t di di diff ffer er ren n nce ces s s w we wer re o o obs bs ser er erve ve ved d a ac acro ro ross ss ss gr gr grou ou oups ps s as s s re re ega ga gard rd ds s s to to o p p pro ro roce ce edu du ura ra al l l da da data ta. .
Analysis of mo mo mort rt r al al alit it i y y y
p<0.001, and HR 1.4 (1.2-2.2), p=0.03, respectively] (Fig 1b) .
The lack of a statistically significant difference in terms of 1-year mortality between patients with severe MR (17%) and moderate MR (12%) could be related to the small sample size. There appears to be a step-wise increase in the risk of mortality across the three groups (none/mild, 10%; moderate, 12%; severe 17%) that might be clinically meaningful.
According Non-Cardiac mortality.
Severe MR was not associated with a higher risk of non-cardiac mortality at 1-month as well as 2.5-3.8, p=0.001) were independent predictors of overall mortality at 1-year. Of f n n note te t , th th he e e mprovement in MR severity, measured at 1-month post TAVR, did not independently predict mo mort rt rtal al alit it ity y (H (H (HR R R 1. .6 6, 6, 0 0.5-2.2; p=0.4).
C C Car rd rdiac Mort rtal al alit ty y.
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Rate of Hospitalization for heart failure and NYHA functional class
At 30-days, the rate of hospitalization for heart failure was significantly higher (7% vs. 3% and 2%), and the percentage of patients with NYHA class I-II significantly lower (74% vs. 90% and 92%) among those with severe MR at baseline (see Table 3a and b). After 30 days to 1-year, these differences were no longer significant. A possible explanation may rely on the observed higher mortality rate in the severe MR group that may have selected a subgroup of patients with a relatively better clinical status.
Mitral regurgitation severity modification at 1-year
Among patients presenting with severe MR at baseline, a significant improvement (>1 grade)
was observed in 47% of cases (see Figure 2 ). In patients with moderate MR (grade 2), a significant improvement was observed in 35%, while in 3% the valve function worsened (>1 grade).
In 8.4% of the cases with mild/none MR, we observed a worsening of MR severity at 1-year (>1 grade). Of note, in the time-window of the study, no patients experienced a >1 grade worsening in MR.
Features of patients according to their initial MR grade and subsequent modifications are listed in Table 4 . Notably, regardless of the severity of MR at baseline, patients with a significant improvement in MR had a significantly lower rate of SPH and AF compared to patients in whom MR was unchanged or worsened. No prosthesis dysfunction was observed in any of the groups.
LVEF and EDV did not significantly change over time within both groups. As is well known, the presence of significant MR may determine an overestimation of the LVEF; indeed the absence of any significant change over time in the LVEF may be due to the balance of both the resolution of Among patients presenting with severe MR at baseline, a significant improveme en nt nt ( ( (> > t 1 1 1 gr gr grad ad ade) e e)
was observed in 47% of cases (see Figure 2 ). In patients with moderate MR (grade 2), a i ign gn nif if ific ic ican an nt t t im im impr rov ov ovem ement was observed in 35%, w w wh hi ile in 3% the va va alve e fu fu fun n nction worsened (>1 g grad d de) e .
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According to Cox-regression analysis, the absence of SPH (HR 2.9, 2.7-3.3, p=0.002), the absence of AF (HR 2.02, 1.88-2.9, p= 0.003), and a functional etiology of MR (HR 2.6,1.8-3.1, p=0.005), were independent predictors of an improvement in MR severity.
Discussion
Compared to patients with mild baseline MR, those with moderate or severe MR have a worse baseline clinical status and have a significantly higher overall and cardiac mortality at 1-month as well as at 1-year after TAVR. Although not statistically significant, patients with severe MR have a considerably higher risk of 1-year mortality with respect to those with moderate MR.
Among patients surviving at 1-year follow up, improved mitral valve function was observed in 47% of the patients with severe MR at baseline, and 35% with moderate MR at baseline. In contrast, a worsening of mitral valve function was reported in only 6.3% of the cases.
The presence of SPH, AF, and MR more than mild/none were independent predictors of mortality. On the other hand, "functional" MR, the absence of SPH or AF independently predicted the observed improvement in MR severity. However, improvement in MR severity post-TAVR was not associated with improved survival.
The clinical impact and evolution of MR after TAVR is still a matter of concern. Some insight can be derived from the surgical experience that reported a worse prognosis in patients undergoing surgical aortic valve replacement with concomitant mitral valve replacement Both Partner A and B results seemed to support the use of TAVR in patients with moderateto-severe MR. They actually reported that these subgroups of patients experienced an even greater benefit with respect to patients without moderate-to-severe MR, resulting in a smaller number needed to treat to prevent a fatality 1, 2 . On the other hand, the presence of moderate or severe MR has been consistently associated with a worse prognosis across several national registries [3] [4] [5] .
The presence of two different devices might add complexity to the interpretation of the scenario. It has been postulated that differences in the structure of the 2 devices may imply a different risk of mitral valve dysfunction; in other words, the longer nitinol frame of the CRS could mechanically interfere with the anterior leaflet of the mitral apparatus, especially in the presence of a low implant 9 . Our data actually rule out this phenomenon as the incidence of a worsened MR was quite low and no difference was observed in the low implantation rate between those with and without a worsened MR ( Table 4) .
It has been also suggested, in a small population of TAVR patients, that an improvement in the MR grade was more likely in patients treated by means of Edwards Sapien transcatheter valve 15 In our cohort of patients treated by means of CRS-TAVR, a significant improvement in the MR severity was observed in a high percentage of patients presenting with moderate or severe MR at baseline.
Recent data from a Canadian registry 7 reported that a moderate or severe MR negatively affected the 1-month but not the 1-year mortality. They also observed an improved MR grade in 55% of surviving patients with moderate or severe MR at baseline. Several key features distinguish cenario. It has been postulated that differences in the structure of the 2 devices ma ma ay y im im impl pl ply y y a a a different risk of mitral valve dysfunction; in other words, the longer nitinol frame of the CRS could me mech ch chan an ani ic ical al ally ly ly int ter er erf fe fere with the anterior leaflet of f f th th t e e e mitral apparat at tu us, e esp sp spe ecially in the presence of a lo ow w implant 9 9 . Ou Ou Our da da data ta a act ct ctua ua ual ll lly y ru ru rul le le o o ou ut t thi is s p p phen n no om men en no on on a a as th the e in n nci cide de denc c ce e o of of n a a w wo or ors se sene ned d d MR MR MR w w wa f f qu quit it ite e lo lo low w an an and d d no no d di if iffe fer r ren nc nce e w wa was s ob ob obse se serv rv ved ed d i i in n n th the e e lo lo ow w im im mpl pl lan an ant t tati ti tion on on rat at ate e e b be etw w wee ee en n n th th t os os se e e wi wit th th a and nd d without a wo ors rs sen en ened ed ed M M MR R R ( (Ta Ta Tabl bl b e 4 4 4). ). ) the present manuscript from the previous: 1) in that publication, the authors examined the outcome of patients in 2 centers treated by means of Cribier-Edwards (12%), the Edwards SAPIEN (60%), and the SAPIEN XT (28%) prostheses; we included patients from 11 centers across the country consisting in a two-fold larger population exclusively treated by means of third generation CoreValve; 2) we separately analyzed patients according to their baseline MR grade (0/1, 2 and 3) with respect to the improvement in MR function; 3) we examined the overall, cardiac and noncardiac mortality at 1-month and 1-year follow up; 4) the 1-year analysis has been done with and without censoring events at 1-month in order to exclude the impact of the survival bias; 5) we evaluated the prognostic significance of MR improvement; 6) we addressed the issue of rehospitalization for heart failure, which may strongly affect the quality of life and health economy.
To the best of our knowledge, the present multicenter registry is the largest available thus far specifically focusing on the interaction of MR and TAVR by means of CRS. To a different extent, both moderate and severe MR determine a worse prognosis compared to mild/none MR, but do not confer a statistically different risk of mortality when compared head-to-head, although in the presence of an evident "step-wise" increased risk of mortality from mild/none to severe MR.
Consistently with data published in smaller populations [6] [7] [8] , an improvement in MR severity was more likely when AF and SPH were not present and when the MR had a "functional" etiology.
The mechanism of improvement in MR severity is clearly multifactorial. The improved aortic valve performance, with the subsequent reduction of the afterload, is conceivably expected to reduce the pathological retrograde flow through the mitral valve. It can also be presumed that the resolution of aortic stenosis may facilitate the achievement of a better hemodynamic balance by reducing the neuro-hormonal activation caused by the heart failure status. The treatment of the hospitalization for heart failure, which may strongly affect the quality of life and he he eal al lth th t e eco o cono no nomy my m .
To the best of our knowledge, the present multicenter registry is the largest available thus far However, an improvement in MR severity did not exert a beneficial effect on survival. It is conceivable that the positive effect of improved mitral valve function could be attenuated by the stronger impact of other negative predictors. Indeed, it has been demonstrated in randomized controlled trials, as well as in several national registries [1] [2] [3] [4] [5] , that there are some key clinical features (renal failure, chronic obstructive pulmonary disease, previous stroke, frailty), and procedural issues such as paravalvular leaks, peri-procedural stroke and bleeding events that may exert a negative impact on early and late outcomes, thus overwhelming the role of an improved valve function.
Limitations of the present study
As obvious in the nature of a registry, the lack of any randomization and differences in local 
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Conclusions
